REnAL denervatIon by ultraSound Transcatheter Emission (REALISE)
Primary Purpose
Resistant Hypertension
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
PARADISE percutaneous renal denervation
Sponsored by

About this trial
This is an interventional treatment trial for Resistant Hypertension focused on measuring Hypertension, Blood pressure, Renal denervation
Eligibility Criteria
Inclusion Criteria:
- Resistant hypertension, as defined in the 2007 ESH-ESC guidelines
- 18 years of age or older
- Negative pregnancy test for female patients of childbearing potential
- Willing and able to comply with follow-up requirements
- Signed informed consent
Exclusion Criteria:
- Secondary hypertension
- Main renal arteries length < 20 mm
- Main renal arteries diameter < 4 mm
- Renal artery stenosis
- Iliac/femoral artery stenosis precluding insertion of the catheter
- Allergy to contrast media
- Currently participating in the study of an investigational drug or device
- Hemodynamics abnormality
- Moderate to severe renal insufficiency
Sites / Locations
- Université de Toulouse et CHU
- Hôpital Pitié-Salpêtrière
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Percutaneous renal denervation
Arm Description
Outcomes
Primary Outcome Measures
Percentage of successful interventions
A successful intervention is defined by the ability to successfully:
Introduce the PRDS catheter
Position the PRDS catheter
Deliver ultrasound energy
Retrieve the PRDS catheter
Percentage of patients with device- or procedure-related adverse events
Anticipated adverse events include:
Puncture site-related events
Renal artery stenosis, aneurysm, dissection, or perforation
Renal infarction, acute kidney injury, or renal failure
Arterial and venous thromboembolic events (including myocardial infarction, stroke, aortic or peripheral artery disease, etc.)
Secondary Outcome Measures
Change from baseline in ambulatory blood pressure
Change from baseline in anti-hypertensive medication intake
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01529372
Brief Title
REnAL denervatIon by ultraSound Transcatheter Emission
Acronym
REALISE
Official Title
REnAL denervatIon by ultraSound Transcatheter Emission
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
March 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ReCor Medical, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The REALISE trial is a single-arm, open-label, prospective, post market evaluation to be conducted on twenty (20) eligible patients with a twelve month follow-up period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Resistant Hypertension
Keywords
Hypertension, Blood pressure, Renal denervation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Percutaneous renal denervation
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
PARADISE percutaneous renal denervation
Other Intervention Name(s)
ReCor Medical PARADISE
Intervention Description
Intravascular ultrasound emission
Primary Outcome Measure Information:
Title
Percentage of successful interventions
Description
A successful intervention is defined by the ability to successfully:
Introduce the PRDS catheter
Position the PRDS catheter
Deliver ultrasound energy
Retrieve the PRDS catheter
Time Frame
Up to 24 hours
Title
Percentage of patients with device- or procedure-related adverse events
Description
Anticipated adverse events include:
Puncture site-related events
Renal artery stenosis, aneurysm, dissection, or perforation
Renal infarction, acute kidney injury, or renal failure
Arterial and venous thromboembolic events (including myocardial infarction, stroke, aortic or peripheral artery disease, etc.)
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Change from baseline in ambulatory blood pressure
Time Frame
12 months
Title
Change from baseline in anti-hypertensive medication intake
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Resistant hypertension, as defined in the 2007 ESH-ESC guidelines
18 years of age or older
Negative pregnancy test for female patients of childbearing potential
Willing and able to comply with follow-up requirements
Signed informed consent
Exclusion Criteria:
Secondary hypertension
Main renal arteries length < 20 mm
Main renal arteries diameter < 4 mm
Renal artery stenosis
Iliac/femoral artery stenosis precluding insertion of the catheter
Allergy to contrast media
Currently participating in the study of an investigational drug or device
Hemodynamics abnormality
Moderate to severe renal insufficiency
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gilles Montalescot, Professor
Organizational Affiliation
Hôpital Pitié-Salpêtrière
Official's Role
Principal Investigator
Facility Information:
Facility Name
Université de Toulouse et CHU
City
Toulouse
ZIP/Postal Code
1048
Country
France
Facility Name
Hôpital Pitié-Salpêtrière
City
Paris
State/Province
Île-de-France
ZIP/Postal Code
75013
Country
France
12. IPD Sharing Statement
Learn more about this trial
REnAL denervatIon by ultraSound Transcatheter Emission
We'll reach out to this number within 24 hrs